PR Newswire (Mon, 8:00AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
6,765 people get LLY articles and Market Currents by email alert.
Get email alerts on LLY »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
PR Newswire (May 14, 2013)
-
PR Newswire (May 14, 2013)
-
-
-
-
PR Newswire (May 10, 2013)
-
-
-
-
PR Newswire (May 6, 2013)
-
PR Newswire (May 6, 2013)
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Eli Lilly: Cymbalta Patent CliffPharma Reports • Thu, Nov 1, 2012
-
-
-
Should Investors Be Concerned About Eli Lilly?Mel Daris • Tue, Oct 23, 2012 -
-
Eli Lilly & Co.'s CEO Discusses Q4 2011 Results - Earnings Call TranscriptTue, Jan 31, 2012 • 1 Comment
-
Eli Lilly & Co.'s CEO Discusses Q3 2011 Results - Earnings Call TranscriptThu, Oct 20, 2011 • 1 Comment
-
Eli Lilly & Co. Q2 2010 Earnings Call TranscriptThu, Jul 22, 2010
-
Eli Lilly and Company Q1 2010 Earnings Call TranscriptMon, Apr 19, 2010 • 1 Comment
-
Eli Lilly and Co. Q4 2009 Earnings Call TranscriptThu, Jan 28, 2010 • 1 Comment
-
Eli Lilly and Company Q3 2009 Earnings Call TranscriptWed, Oct 21, 2009
-
PR Newswire (May 14, 2013)
-
PR Newswire (May 14, 2013)
-
at Fox Business (May 10, 2013)
-
PR Newswire (May 10, 2013)
-
at CNBC.com (May 7, 2013)
-
PR Newswire (May 6, 2013)
-
PR Newswire (May 6, 2013)
-
PR Newswire (Apr 30, 2013)
-
PR Newswire (Apr 26, 2013)
-
at CNBC.com (Apr 24, 2013)
-
PR Newswire (Apr 24, 2013)
-
at MarketWatch.com (Apr 24, 2013)
-
at CNBC.com (Apr 24, 2013)
-
at CNBC.com (Apr 24, 2013)
-
PR Newswire (Apr 24, 2013)
-
at CNBC.com (Apr 20, 2013)
LLY vs. ETF Alternatives
Company Description
Eli Lilly and Company (the “Company” or “Registrant”) was incorporated in 1901 in Indiana to succeed to the drug manufacturing business founded in Indianapolis, Indiana, in 1876 by Colonel Eli Lilly. We discover, develop, manufacture, and sell products in one significant business... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, October 30, 2012, 10:31 AM Levels of beta amyloid, a protein linked with Alzheimer's, increased in the blood of patients treated with Eli Lilly's (LLY) solanezumab in two Phase III trials, suggesting that the protein was removed from the brain as intended. As already disclosed, Solanezumab seems to be able to slow Alzheimer's progression in patients with mild symptoms, so the latest finding provides validity to the belief that amyloid is a cause. 2 Comments [Healthcare]
- Wednesday, October 24, 2012, 8:51 AM More on Eli Lilly (LLY -1.7%) Q3: net profit +7% to $1.33B, boosted by payment from former partner Amylin. Sales breakdown: antidepressant Cymbalta +16% to $1.24B, cancer drug Alimta +2% to $643.6M. Antipsychotic Zyprexa -68% to $374.5M, due to patent loss; animal-health products +6% to $479.4M. Reiterates 2012 guidance. Comment! [Earnings, Healthcare]
- Wednesday, October 24, 2012, 6:32 AM Eli Lilly (LLY): Q3 EPS of $0.79 misses by $0.03. Revenue of $5.44B (-11% Y/Y) misses by $170M. (PR) Comment! [Earnings, Healthcare]
- Wednesday, October 24, 2012, 12:05 AM Notable earnings before Wednesday’s open: AEP, ALXN, ATI, BA, BMY, CP, DAL, DPS, DTE, EAT, ECA, ELN, EMC, GD, GLW, HCBK, IACI, KMB, LCC, LL, LLY, LMT, LO, LVLT, MSI, NDAQ, NEE, NOC, NYB, OC, PVR, PX, RCI, REGN, RES, SAP, T, TMO, TROW, WYN Comment! [Earnings]
- Tuesday, October 23, 2012, 5:30 PM Notable earnings before Wednesday’s open: AEP, ALXN, ATI, BA, BMY, CP, DAL, DPS, DTE, EAT, ECA, ELN, EMC, GD, GLW, HCBK, IACI, KMB, LCC, LL, LLY, LMT, LO, LVLT, MSI, NDAQ, NEE, NOC, NYB, OC, PVR, PX, RCI, REGN, RES, SAP, T, TMO, TROW, WYN Comment! [Earnings]
- Monday, October 22, 2012, 8:58 AM Eli Lilly's (LLY +0.2%) dulaglutide treatment for type 2 diabetes performs well in three Phase III studies, meeting the primary endpoints as measured by lower levels of hemoglobin A1c, which helps indicate blood sugar control. The most frequently reported side-effects were gastrointestinal-related. Other studies of dulaglutide are taking place, with two due to conclude in the next few months. (PR) 2 Comments [Healthcare]
- Friday, October 19, 2012, 3:57 PM Eli Lilly (LLY -1.8%) says it's received a positive opinion from the Committee for Medicinal Products for Human Use in Europe recommending approval of Amyvid, a solution for injection as a diagnostic radiopharmaceutical in the brains of adult patients being evaluated for Alzheimer's Disease and other causes of cognitive impairment. Comment! [Healthcare, Global & FX]
- Wednesday, October 17, 2012, 4:46 PM The FDA has approved a new use for Eli Lilly's (LLY) lung cancer treatment Alimta, now saying that patients may receive the drug as a maintenance therapy following first-line treatment. The FDA cites Phase III data, the first of its kind, that demonstrates better overall survival advantages with continued maintenance. Shares +1% AH. Comment! [Healthcare]
- Monday, October 15, 2012, 4:20 PM Eli Lilly (LLY) declares $0.49/share quarterly dividend, in line with previous. Forward yield 3.89%. For shareholders of record Nov 15. Payable Dec 10. Ex-div date Nov 13. (PR) 1 Comment [Dividends]
- Monday, October 15, 2012, 10:52 AM Leerink Swann ups Eli Lilly (LLY +5.3%) to Outperform and raises sales estimates on the back of positive trial results for its gastric cancer treatment, ramucirumab. The firm thinks the recently released data shows encouraging potential for use on other tumor types, which could boost sales and lower the drug's overall marketing risk outlook. Comment! [Healthcare, On the Move]
- Monday, October 15, 2012, 8:55 AM Eli Lilly's (LLY) ramucirumab drug for gastric cancer meets its main goal of improving overall survival in a Phase III study, with the treatment also increasing survival without the cancer worsening. Shares +1.8% premarket. (PR) Comment! [Healthcare]
- Wednesday, October 10, 2012, 1:09 PM Washington University in St. Louis says it's selected Roche's (RHHBY.PK) gantenerumab and Eli Lilly's (LLY -2.9%) solanezumab and beta secretase inhibitor for Alzheimer's prevention trials, expected to begin early 2013. The trials will be conducted the university's Dominantly Inherited Alzheimer's Network Trials Unit, and is expected to involve 160 people with inherited gene mutations that typically lead to alzheimer's at young age. Comment! [Healthcare]
- Tuesday, October 9, 2012, 9:33 AM Eli Lilly (LLY) may have jumped 5.3% yesterday and added $3B to its market cap following news that its Solanezumab drug helped slow the progress of Alzheimer's Disease in Phase III trials, but SA author Brian Wilson points out that "the results were not statistically significant." This means that the study can't be used for an NDA submission of solanezumab, which is therefore "not going to make it to...market." 1 Comment [Healthcare, Quick Ideas, On the Move]
- Tuesday, October 9, 2012, 7:41 AM On the back of positive results for its Alzheimer's treatment, Eli Lilly (LLY) is upgraded to Neutral with $54 price target from Sell and $42 at Goldman. "Our skepticism was proven wrong." Shares +1% premarket. Comment! [Healthcare]
- Monday, October 8, 2012, 1:59 PM Eli Lilly (LLY +2.6%) pops after a new study shows its experimental Alzheimer’s treatment slowed memory loss and cognitive decline in early-stage patients by ~30%, offering the first evidence that a medication may hamper the course of the ailment. The independent study supports LLY’s August report that showed the drug, solanezumab, slowed mental decline in those with mild Alzheimer’s. 1 Comment [Healthcare, On the Move]
- Tuesday, October 2, 2012, 8:34 AM Eli Lilly (LLY) and Boehringer Ingelheim's empagliflozin drug reduced blood pressure in patients with Type II diabetes in two Phase IIb trials. Meanwhile, the companies' Analogue insulin performed well in a Phase II study, as did the already-approved Tradjenta for controlling blood sugar levels in elderly patients with type 2 diabetes in three trials. Comment! [Healthcare]
-
- View all 0 replies
-
- View all 2 replies
-
-
-
- View all 4 replies
-
-
-
- View all 8 replies
-
-
-
- View all 0 replies
-
- View all 1 replies
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES